Phytochemicals in Alzheimer disease: The development of clinical trials

被引:5
|
作者
Quinn, J
Kaye, J
Montine, T
Stackman, R
机构
[1] Portland VA Med Ctr, Dept Neurol, Portland, OR 97201 USA
[2] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA
[3] Univ Washington, Med Ctr, Dept Pathol, Seattle, WA 98195 USA
关键词
Alzheimer disease; antioxidants; oxidative stress; polyphenolics;
D O I
10.3109/138802090893531
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Polyphenolics and other phytochemicals may have a role in the prevention or treatment of Alzheimer disease. Targets of therapy in Alzheimer disease include neurotransmitter deficits, beta amyloid neurotoxicity, oxidative damage, and inflammation, to name a few. Challenges to the development of phytochemical and other neuroprotectant therapy in Alzheimer disease include the inability to measure pathology in living patients and the challenge of detecting modification of an indolent disease course. These challenges are partially surmounted by the use of animal models and of biomarkers of disease. This review describes currently available animal models and biomarkers and surveys clinical trials of phytochemical therapies that. are recently completed or currently under way. Both animal studies and clinical trials of Ginkgo biloba are described, as well as a trial of Uncaria tomentosa that has not been previously reported.
引用
收藏
页码:64 / 73
页数:10
相关论文
共 50 条
  • [21] THE ROLE OF EEG IN CLINICAL TRIALS ON ALZHEIMER'S DISEASE
    van Straaten, Ilse
    Scheltens, P.
    Stam, C. J.
    NEUROBIOLOGY OF AGING, 2014, 35 : S23 - S23
  • [22] Applications of Alzheimer's disease staging to clinical trials
    Therriault, Joseph
    Gauthier, Serge
    Rosa-Neto, Pedro
    AGING-US, 2023, 15 (01): : 1 - 2
  • [23] Alzheimer's Disease: Clinical Trials and the Amyloid Hypothesis
    Cummings, Jeffrey
    ANNALS ACADEMY OF MEDICINE SINGAPORE, 2011, 40 (07) : 304 - 306
  • [24] Therapeutic strategies for Alzheimer’s disease in clinical trials
    Justyna Godyń
    Jakub Jończyk
    Dawid Panek
    Barbara Malawska
    Pharmacological Reports, 2016, 68 : 127 - 138
  • [25] Biochemical markers in Alzheimer's disease clinical trials
    Zetterberg, Henrik
    Mattsson, Niklas
    Shaw, Les M.
    Blennow, Kaj
    BIOMARKERS IN MEDICINE, 2010, 4 (01) : 91 - 98
  • [26] Clinical Trials of Intravenous Immunoglobulin for Alzheimer’s Disease
    Norman Relkin
    Journal of Clinical Immunology, 2014, 34 : 74 - 79
  • [27] NEUROIMAGING OUTCOMES IN CLINICAL TRIALS IN ALZHEIMER'S DISEASE
    Frisoni, G. B.
    Delacourte, A.
    JOURNAL OF NUTRITION HEALTH & AGING, 2009, 13 (03): : 209 - 212
  • [28] Clinical Trials of Intravenous Immunoglobulin for Alzheimer's Disease
    Relkin, Norman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 : S74 - S79
  • [29] Improving Clinical Trials of Antioxidants in Alzheimer's Disease
    Daly, Timothy
    JOURNAL OF ALZHEIMERS DISEASE, 2024, 99 : S171 - S181
  • [30] Therapeutic strategies for Alzheimer's disease in clinical trials
    Godyn, Justyna
    Jonczyk, Jakub
    Panek, Dawid
    Malawska, Barbara
    PHARMACOLOGICAL REPORTS, 2016, 68 (01) : 127 - 138